Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $110 to $127.
December 13, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Neurocrine Biosciences and raised the price target from $110 to $127, indicating a positive outlook on the stock.
The increase in the price target by a reputable analyst suggests a positive outlook on the stock's value, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100